These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 26147584)

  • 1. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
    Landgren O; Owen RG
    Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
    Rawstron AC; Paiva B; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
    Rawstron AC; de Tute RM; Haughton J; Owen RG
    Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
    Gormley NJ; Turley DM; Dickey JS; Farrell AT; Reaman GH; Stafford E; Carrington L; Marti GE
    Cytometry B Clin Cytom; 2016 Jan; 90(1):73-80. PubMed ID: 26108351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
    Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
    Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
    [No Abstract]   [Full Text] [Related]  

  • 7. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.
    de Tute RM; Rawstron AC; Gregory WM; Child JA; Davies FE; Bell SE; Cook G; Szubert AJ; Drayson MT; Jackson GH; Morgan GJ; Owen RG
    Haematologica; 2016 Feb; 101(2):e69-71. PubMed ID: 26471484
    [No Abstract]   [Full Text] [Related]  

  • 9. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.
    Oldaker TA; Wallace PK; Barnett D
    Cytometry B Clin Cytom; 2016 Jan; 90(1):40-6. PubMed ID: 26201282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
    Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG
    J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
    Landgren O; Devlin S; Boulad M; Mailankody S
    Bone Marrow Transplant; 2016 Dec; 51(12):1565-1568. PubMed ID: 27595280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
    Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
    Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.
    Jimenez-Zepeda VH; Duggan P; Neri P; Chaudhry A; Murray K; Culham M; Luider J; Fourie T; Rashid-Kolvear F; Bahlis NJ
    Leuk Lymphoma; 2016; 57(4):973-6. PubMed ID: 26450458
    [No Abstract]   [Full Text] [Related]  

  • 19. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
    Stetler-Stevenson M; Paiva B; Stoolman L; Lin P; Jorgensen JL; Orfao A; Van Dongen J; Rawstron AC
    Cytometry B Clin Cytom; 2016 Jan; 90(1):26-30. PubMed ID: 25907102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.